M
Michael F. Marmor
Researcher at Stanford University
Publications - 271
Citations - 15631
Michael F. Marmor is an academic researcher from Stanford University. The author has contributed to research in topics: Retinal & Retinal pigment epithelium. The author has an hindex of 57, co-authored 271 publications receiving 14204 citations. Previous affiliations of Michael F. Marmor include University of Miami & Saint Louis University.
Papers
More filters
Journal ArticleDOI
ISCEV Standard for full-field clinical electroretinography (2008 update)
TL;DR: The parameters for flash stimulation and background adaptation have been tightened, and responses renamed to indicate the flash strength (in cd·s·m−2).
Journal ArticleDOI
ISCEV Standard for full-field clinical electroretinography (2015 update)
Daphne L. McCulloch,Michael F. Marmor,Mitchell Brigell,Ruth Hamilton,Ruth Hamilton,Graham E. Holder,Radouil Tzekov,Michael Bach +7 more
TL;DR: An updated and revised ISCEV Standard for full-field clinical electroretinography (ffERG or simply ERG) is presented and the parameters for Standard flash stimuli have been revised to accommodate a variety of light sources including gas discharge lamps and light emitting diodes.
Journal ArticleDOI
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
TL;DR: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools.
Journal ArticleDOI
Standard for clinical electroretinography
TL;DR: The full-field electroretinogram (ERG) is a widely used ocular electrophysiological test and a basic protocol should be standardized so that certain responses will be recorded comparably throughout the world.
Journal ArticleDOI
Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy
TL;DR: Patients should be aware of the risk of toxicity and the rationale for screening (to detect early changes and minimize visual loss, not necessarily to prevent it), and the drugs should be stopped if possible when toxicity is recognized or strongly suspected.